Commitments and contingencies (Schedule of contingent consideration) (Details) - Antev Limited [Member]	Jun. 30, 2026 USD ($) $ / shares
Advanced Prostate Cancer - Phase 2 success or registration [Member]
Business Combination, Contingent Consideration [Line Items]
Contingent Consideration, price per share \| $ / shares	$ 1.47
Advanced Prostate Cancer - Phase 2 success or registration [Member] \| Common Stock [Member]
Business Combination, Contingent Consideration [Line Items]
Contingent Consideration, price per share \| $ / shares	$ 2
Contingent Consideration \| $	$ 5,333,200
Acute Urinary Retention (AUR) Prevention - Phase 2 success or registration [Member]
Business Combination, Contingent Consideration [Line Items]
Contingent Consideration, price per share \| $ / shares	$ 5.52
Contingent Consideration \| $	$ 19,999,500
Acute Urinary Retention (AUR) Prevention - Phase 2 success or registration [Member] \| Common Stock [Member]
Business Combination, Contingent Consideration [Line Items]
Contingent Consideration, price per share \| $ / shares	$ 7.5
FDA NDA approval - Hormone therapy for prostate cancer [Member]
Business Combination, Contingent Consideration [Line Items]
Contingent Consideration, price per share \| $ / shares	$ 5.52
Contingent Consideration \| $	$ 20,000,000
FDA NDA approval - Hormone therapy for prostate cancer [Member] \| Maximum [Member]
Business Combination, Contingent Consideration [Line Items]
Contingent Consideration \| $	$ 20,000,000
FDA NDA approval - AUR prevention [Member]
Business Combination, Contingent Consideration [Line Items]
Contingent Consideration, price per share \| $ / shares	$ 5.52
Contingent Consideration \| $	$ 20,000,000
FDA NDA approval - AUR prevention [Member] \| Maximum [Member]
Business Combination, Contingent Consideration [Line Items]
Contingent Consideration \| $	$ 20,000,000